Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma
YS Lu, Y Kashida, SK Kulp, YC Wang, D Wang… - Hepatology, 2007 - journals.lww.com
Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide, yet effective
therapeutic options for advanced HCC are limited. This study was aimed at assessing the
antitumor effect of a novel phenylbutyrate-derived histone deacetylase (HDAC) inhibitor,
OSU-HDAC42, vis-à-vis suberoylanilide hydroxamic acid (SAHA), inin vitroandin
vivomodels of human HCC. OSU-HDAC42 was several times more potent than SAHA in
suppressing the viability of PLC5, Huh7, and Hep3B cells with submicromolar median …
therapeutic options for advanced HCC are limited. This study was aimed at assessing the
antitumor effect of a novel phenylbutyrate-derived histone deacetylase (HDAC) inhibitor,
OSU-HDAC42, vis-à-vis suberoylanilide hydroxamic acid (SAHA), inin vitroandin
vivomodels of human HCC. OSU-HDAC42 was several times more potent than SAHA in
suppressing the viability of PLC5, Huh7, and Hep3B cells with submicromolar median …